TP53 and breast carcinoma: In terms of the Chompret criteria item “juvenile breast cancer,” the ratio of individuals with TP53 pathogenic variant in patients with normal breast cancer patients, breast cancer patients with premenopausal onset, and breast cancer patients with a family history of breast cancer was 0–1.0% [47–52], 0–3.8% [50, 53–57], and 1.0–2.9% [58, 59], respectively.